AZ starts phase 2/3 trial of new-variant COVID-19 vaccineAstraZeneca and Oxford University have started dosing patients in a trial of a new version of their COVID-19 Share XAZ starts phase 2/3 trial of new-variant COVID-19 vaccinehttps://pharmaphorum.com/news/az-starts-phase-2-3-trial-of-new-variant-covid-19-vaccine/
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 JanuaryThe European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its Share XEMA says AstraZeneca’s COVID-19 shot could be approved on 29 Januaryhttps://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/
AZ COVID-19 vaccine cleared in UK, dosing to start next weekThe UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the Share XAZ COVID-19 vaccine cleared in UK, dosing to start next weekhttps://pharmaphorum.com/news/az-covid-19-vaccine-cleared-in-uk-dosing-to-start-next-week/
AZ expands phase 3 trials of COVID-19 vaccine frontrunner into USAstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across Share XAZ expands phase 3 trials of COVID-19 vaccine frontrunner into UShttps://pharmaphorum.com/news/az-expands-phase-3-trials-of-covid-19-vaccine-frontrunner-into-us/
The power of crowdsourced R&DDrug R&D is still dogged by attrition, duplication and waste. Chas Bountra, chief scientist & head of the Share XThe power of crowdsourced R&Dhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/crowdsourcing-rd/
